PMID- 22613584
OWN - NLM
STAT- MEDLINE
DCOM- 20121207
LR  - 20211021
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 14
IP  - 8
DP  - 2012 Aug
TI  - Treatment of functional mitral regurgitation by percutaneous annuloplasty: 
      results of the TITAN Trial.
PG  - 931-8
LID - 10.1093/eurjhf/hfs076 [doi]
AB  - AIMS: Functional mitral regurgitation (FMR) contributes to morbidity and 
      mortality in heart failure (HF) patients. The aim of this study was to determine 
      whether percutaneous mitral annuloplasty could safely and effectively reduce FMR 
      and yield durable long-term clinical benefit. METHODS AND RESULTS: The impact of 
      mitral annuloplasty (Carillon Mitral Contour System) was evaluated in HF patients 
      with at least moderate FMR. Patients in whom the device was placed then acutely 
      recaptured for clinical reasons served as a comparator group. Quantitative 
      measures of FMR, left ventricular (LV) dimensions, New York Heart Association 
      (NYHA) class, 6 min walk distance (6MWD), and quality of life were assessed in 
      both groups up to 12 months. Safety and key functional data were assessed in the 
      implanted cohort up to 24 months. Thirty-six patients received a permanent 
      implant; 17 had the device recaptured. The 30-day major adverse event rate was 
      1.9%. In contrast to the comparison group, the implanted cohort demonstrated 
      significant reductions in FMR as represented by regurgitant volume [baseline 34.5 
      +/-11.5 mL to 17.4 +/-12.4 mL at 12 months (P < 0.001)]. There was a corresponding 
      reduction in LV diastolic volume [baseline 208.5 +/-62.0 mL to 178.9 +/-48.0 mL at 12 
      months (P =0.015)] and systolic volume [baseline 151.8 +/-57.1 mL to 120.7 +/-43.2 mL 
      at 12 months (P =0.015)], compared with progressive LV dilation in the 
      comparator. The 6MWD markedly improved for the implanted patients by 102.5 +/-164 m 
      at 12 months (P =0.014) and 131.9 +/-80 m at 24 months (P < 0.001). CONCLUSION: 
      Percutaneous reduction of FMR using a coronary sinus approach is associated with 
      reverse LV remodelling. Significant clinical improvements persisted up to 24 
      months.
FAU - Siminiak, Tomasz
AU  - Siminiak T
AD  - Department of Cardiology, Poznan University, Poznan, Poland.
FAU - Wu, Justina C
AU  - Wu JC
FAU - Haude, Michael
AU  - Haude M
FAU - Hoppe, Uta C
AU  - Hoppe UC
FAU - Sadowski, Jerzy
AU  - Sadowski J
FAU - Lipiecki, Janusz
AU  - Lipiecki J
FAU - Fajadet, Jean
AU  - Fajadet J
FAU - Shah, Amil M
AU  - Shah AM
FAU - Feldman, Ted
AU  - Feldman T
FAU - Kaye, David M
AU  - Kaye DM
FAU - Goldberg, Steven L
AU  - Goldberg SL
FAU - Levy, Wayne C
AU  - Levy WC
FAU - Solomon, Scott D
AU  - Solomon SD
FAU - Reuter, David G
AU  - Reuter DG
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20120521
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
SB  - IM
MH  - Analysis of Variance
MH  - Exercise Test
MH  - Exercise Tolerance
MH  - Female
MH  - Health Status Indicators
MH  - Heart Failure/diagnostic imaging/pathology/*surgery
MH  - Heart Valve Prosthesis Implantation/*methods
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Annuloplasty/*methods
MH  - Mitral Valve Insufficiency/*surgery
MH  - Prospective Studies
MH  - Quality of Life/psychology
MH  - Risk Factors
MH  - Stroke Volume
MH  - Time Factors
MH  - Ultrasonography
MH  - Ventricular Function, Left
PMC - PMC3403476
EDAT- 2012/05/23 06:00
MHDA- 2012/12/12 06:00
PMCR- 2012/05/21
CRDT- 2012/05/23 06:00
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
PHST- 2012/05/21 00:00 [pmc-release]
AID - hfs076 [pii]
AID - 10.1093/eurjhf/hfs076 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2012 Aug;14(8):931-8. doi: 10.1093/eurjhf/hfs076. Epub 2012 May 
      21.